Evidence map›Paper›PMID 35147070›Full record

ArticleDrug delivery2022

The combination of MnO

Jisong Zhang, Li Xu, Huihui Hu, Enguo Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Nanotechnology boosts the efficiency of tumor diagnosis and therapy.Frontiers in bioengineering and biotechnology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jisong ZhangDepartment of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, School of Medicine, Cancer Center, Zhejiang University, Hangzhou, China.
Li XuDepartment of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, School of Medicine, Cancer Center, Zhejiang University, Hangzhou, China.
Huihui HuDepartment of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, School of Medicine, Cancer Center, Zhejiang University, Hangzhou, China.
Enguo ChenDepartment of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, School of Medicine, Cancer Center, Zhejiang University, Hangzhou, China.
Zhejiang University · CNSir Run Run Shaw Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It can be found from a large number of cancer treatments that use of anti-cancer drugs alone often presents low efficacy and high side effects. This study aims to develop a new drug carrier with tumor-specific response, controlled release

Indexed as

AnimalsAntineoplastic AgentsApoptosisBevacizumabCarcinoma, Non-Small-Cell LungCell Line, TumorCell SurvivalChemistry, PharmaceuticalDelayed-Action PreparationsDrug CarriersDrug CombinationsDrug LiberationGefitinibHumansHydrogen-Ion ConcentrationLung NeoplasmsAntineoplastic AgentsBevacizumabDelayed-Action PreparationsDrug CarriersDrug CombinationsGefitinibManganese Compoundsmanganese dioxideOxidesbiocompatibilityNSCLCpH-sensitiveSpecific response

Identifiers

PMID35147070
PMCPMC8843201
OpenAlexW4211082136

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.